AKUMS DRUGS & PHARMACEUTICALS
|
AKUMS DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 22.09 | -0.28 | 6.63 | -35.30 | 943.16 |
| CEPS(Rs) | 32.48 | 8.84 | 14.72 | -10.92 | 13.48 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 199.01 | 49.59 | 50.13 | 86.95 | 6,801.28 |
| Tax Rate(%) | 0.43 | 101.74 | 34.92 | -29.85 | 28.40 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.18 | 2.94 | 8.04 | -2.50 | 10.69 |
| EBIT Margin(%) | 9.22 | 0.13 | 5.38 | -4.81 | 6.56 |
| Pre Tax Margin(%) | 8.38 | -1.08 | 4.11 | -5.26 | 6.31 |
| PAT Margin (%) | 8.35 | 0.02 | 2.68 | -6.83 | 4.52 |
| Cash Profit Margin (%) | 12.07 | 3.03 | 5.76 | -4.25 | 7.09 |
| Performance Ratios | |||||
| ROA(%) | 9.42 | 0.02 | 3.11 | -9.64 | 5.88 |
| ROE(%) | 18.30 | 0.11 | 14.61 | -33.30 | 15.32 |
| ROCE(%) | 17.83 | 0.43 | 17.59 | -18.00 | 19.01 |
| Asset Turnover(x) | 1.13 | 1.26 | 1.16 | 1.41 | 1.30 |
| Sales/Fixed Asset(x) | 1.99 | 2.32 | 2.24 | 2.56 | 2.35 |
| Working Capital/Sales(x) | 2.98 | 5.72 | 5.96 | 6.21 | 4.71 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.43 | 0.45 | 0.39 | 0.43 |
| Receivable days | 71.09 | 73.33 | 86.36 | 70.36 | 74.60 |
| Inventory Days | 58.11 | 59.41 | 72.52 | 57.27 | 55.51 |
| Payable days | 88.12 | 78.67 | 92.84 | 72.46 | 82.54 |
| Valuation Parameters | |||||
| PER(x) | 21.49 | - | - | - | - |
| PCE(x) | 14.61 | - | - | - | - |
| Price/Book(x) | 2.38 | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.63 | 0.06 | 0.11 | 0.07 | 0.01 |
| EV/Core EBITDA(x) | 12.98 | 1.55 | 1.08 | -3.90 | 0.10 |
| EV/EBIT(x) | 17.65 | 45.56 | 2.11 | -1.53 | 0.17 |
| EV/CE(x) | 2.19 | 0.20 | 0.33 | 0.27 | 0.03 |
| M Cap / Sales | 1.76 | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -1.44 | 14.32 | -0.46 | 34.87 | 12.78 |
| Core EBITDA Growth(%) | 229.02 | -59.12 | 655.88 | -122.12 | 54.92 |
| EBIT Growth(%) | 7,018.68 | -97.29 | 211.33 | -198.82 | 33.57 |
| PAT Growth(%) | - | -99.19 | 138.99 | -303.82 | 181.97 |
| EPS Growth(%) | 7,932.55 | -104.25 | 118.78 | -103.74 | 156.73 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.69 | 0.75 | 0.58 | 0.11 |
| Current Ratio(x) | 2.55 | 1.60 | 1.48 | 1.46 | 2.00 |
| Quick Ratio(x) | 1.78 | 1.08 | 0.91 | 0.90 | 1.26 |
| Interest Cover(x) | 10.98 | 0.11 | 4.25 | -10.60 | 26.49 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of AKUMS DRUGS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AKUMS DRUGS & PHARMACEUTICALS | ₹8,346.1 Cr | -2.7% | -9.1% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,551.0 Cr | 0.4% | 1.8% | 4.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,704.0 Cr | -1.1% | 0.1% | 45.6% | Stock Analytics | |
| CIPLA | ₹123,675.0 Cr | 3.8% | 1.2% | -1.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,925.0 Cr | 2.2% | 11.7% | 11.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,626.0 Cr | 1.4% | -3.3% | -7.2% | Stock Analytics | |
AKUMS DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AKUMS DRUGS & PHARMACEUTICALS | -2.7% |
-9.1% |
|
| SENSEX | -0.4% |
-1.6% |
1.3% |
You may also like the below Video Courses
